Vical licenses vaccine technology to Cyvax

Vical says privately held Cyvax will use its Vaxfectin technology in malaria vaccines

Associated Press

SAN DIEGO (AP) -- Vical Inc. said Wednesday that it licensed its Vaxfectin technology, which is designed to make vaccines more effective, to a company that intends to use it in malaria vaccines.

Vical said privately held Cyvax is licensing Vaxfectin. The companies did not disclose financial terms of the agreement.

Vical also announced a licensing agreement with drugmaker Bristol-Myers Squibb Co. in September.

Shares of Vical declined a penny to $3 in morning trading.

View Comments